Chimeric antigen receptor T cells (CAR T) cancer therapies are advanced and high-value therapies that enhance the immune response against tumor cells. Tumor specificity is achieved by genetically modifying T-cells. As of 2019, two of such therapies were available in the US and some EU markets, both targeting the CD19 antigen. The latter is expressed in cancers such as diffuse large B-cell lymphoma. The development of new CAR T-cell therapies is going towards new antigen targets and limiting the adverse effects.
0
